Showing 1111-1120 of 1484 results for "".
- Neurotech Pharmaceuticals Granted Fast Track Designation from the FDA for the Treatment of Macular Telangiectasia Type 2https://modernod.com/news/neurotech-pharmaceuticals-granted-fast-track-designation-from-the-fda-for-the-treatment-of-macular-telangiectasia-type-2/2476300/Neurotech Pharmaceuticals announced that the FDA has granted Fast Track designation for the company’s development candidate, NT-501 or Renexus, for the treatment of macular telangiectasia type 2 (MacTel). Fast track is a designation by the FDA to facilitate the development and expedite the
- 4D Molecular Therapeutics Announces FDA Orphan Drug Designation Granted to 4D-110 for the Treatment of Choroideremiahttps://modernod.com/news/4d-molecular-therapeutics-announces-fda-orphan-drug-designation-granted-to-4d-110-for-the-treatment-of-choroideremia/2479659/Gene therapy company 4D Molecular Therapeutics (4DMT) announced that the FDA has granted orphan drug designation to 4D-110 for the treatment of choroideremia. Choroideremia (CHM) is an X-linked monogenic recessive disease (caused by mutation of the REP-1 gene) starting with reduced night v
- SiteOne Therapeutics Receives NIH Grant to Support the Development of Novel Therapeutics to Treat Ocular Painhttps://modernod.com/news/siteone-therapeutics-receives-nih-grant-to-support-the-development-of-novel-therapeutics-to-treat-ocular-pain/2479849/SiteOne Therapeutics announced that the company has been awarded a $1.4 million, 2-year, phase 2 SBIR grant from the National Eye Institute (NEI), a member of the US National Institutes of Health (NIH). The award will be used to initiate IND-enabling studies for Site
- FDA Grants Lin BioScience Rare Pediatric Disease Status for LBS-008 to Treat Stargardt Diseasehttps://modernod.com/news/fda-grants-lin-bioscience-rare-pediatric-disease-status-for-lbs-008-to-treat-stargardt-disease/2479877/Lin BioScience announced that the FDA has granted rare pediatric disease (RPD) designation to LBS-008, a first-in-class oral therapy for the treatment of Stargardt Disease. The Priority Review Voucher Program is intended to encourage development of therapies to prevent and treat rare pedi
- MeiraGTx Announces AAV-CNGA3 Granted Rare Pediatric Disease Designation by the U.S. FDA for the Treatment of Achromatopsiahttps://modernod.com/news/meiragtx-announces-aav-cnga3-granted-rare-pediatric-disease-designation-by-the-u-s-fda-for-the-treatment-of-achromatopsia/2479906/Gene therapy company MeiraGTx Holdings announced that the FDA has granted rare pediatric disease designation to the company’s gene therapy product candidate AAV-CNGA3 for the treatment of patients with achromatopsia (ACHM) due to mutations in the CNGA3 gene. ACHM is an inherited r
- MeiraGTx Announces AAV-CNGB3 Granted Fast Track Designation by FDA for Treatment of Achromatopsiahttps://modernod.com/news/meiragtx-announces-aav-cngb3-granted-fast-track-designation-by-fda-for-treatment-of-achromatopsia/2479927/MeiraGTx Holdings announced that the FDA has granted Fast Track designation for its AAV-CNGB3 gene therapy product candidate for the treatment of achromatopsia (ACHM) caused by mutations in the CNGB3 gene. ACHM is an inherited retinal disease that severely limits a person’s sight
- Julie Schornack, OD, Named First Female President of Marshall B. Ketchum Universityhttps://modernod.com/news/julie-schornack-od-named-first-female-president-of-marshall-b-ketchum-university/2481585/Marshall B. Ketchum University (MBKU), an independent, private, non-profit, accredited educational institution in Fullerton, California has introduced Julie A. Schornack, OD, MEd, as its next president to lead the university. Dr. Schornack is the first female p
- OD-OS Presents Navilas Laser System Pro 577s Navigated Retinal Laserhttps://modernod.com/news/od-os-presents-navilas-pro-as-an-affordable-entry-to-the-digital-ecosystem-of-navigated-laser/2478358/At the first virtual Euretina Congress, OD-OS presented the the Navilas Laser System 577s Pro for navigated retinal laser therapy. The Navilas Laser System 577s Pro supports precise and fast treatments of common retinal diseases, according to a company news release. It comes with the core trackin
- CooperVision’s Michele Andrews, OD, Wins 2019 Theia Excellence Award from Women in Optometryhttps://modernod.com/news/coopervisions-michele-andrews-od-wins-2019-theia-excellence-award-from-women-in-optometry/2477045/For her significant contributions to the advancement of the industry and optometric profession, Michele Andrews, OD, Senior Director of Professional and Academic Affairs, North America, CooperVision, has been named a 2019 recipient of Women in Optometry’s Theia Excellence Awards. Dr. And
- Alcon Names Carla Mack, OD, Global Head of Professional Affairs for Vision Carehttps://modernod.com/news/alcon-names-carla-mack-od-global-head-of-professional-affairs-for-vision-care/2476847/Alcon has announced that Carla Mack, OD, has been named Global Head, Professional Affairs. In her new role, Dr. Mack leads professional affairs within Alcon’s Global Vision Care Franchise, reporting to Andy Pawson, President and General Manager, Global Vision Care Franchise. As Global Head